Fundamental Analysis of INFLARX NV(NASDAQ:IFRX) stock

Fundamental Rating

IFRX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. The financial health of IFRX is average, but there are quite some concerns on its profitability. IFRX does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year IFRX has reported negative net income.

In the past year IFRX has reported a negative cash flow from operations.

IFRX had negative earnings in each of the past 5 years.

IFRX had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a decent Return On Assets value of -35.49%, IFRX is doing good in the industry, outperforming 65.53% of the companies in the same industry.

IFRX has a better Return On Equity (-41.59%) than 74.06% of its industry peers.

		Industry Rank	Sector Rank
ROA	-35.49%
ROE	-41.59%
ROIC	N/A

ROA(3y)-33.59%

ROA(5y)-36.62%

ROE(3y)-39.44%

ROE(5y)-42.33%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for IFRX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IFRX does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IFRX has more shares outstanding

Compared to 5 years ago, IFRX has more shares outstanding

IFRX has a better debt/assets ratio than last year.

2.2 Solvency

IFRX has an Altman-Z score of -0.59. This is a bad value and indicates that IFRX is not financially healthy and even has some risk of bankruptcy.

IFRX has a Altman-Z score of -0.59. This is comparable to the rest of the industry: IFRX outperforms 56.66% of its industry peers.

A Debt/Equity ratio of 0.01 indicates that IFRX is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.01, IFRX perfoms like the industry average, outperforming 46.42% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF	N/A
Altman-Z	-0.59

ROIC/WACCN/A

WACC6.91%

2.3 Liquidity

IFRX has a Current Ratio of 6.50. This indicates that IFRX is financially healthy and has no problem in meeting its short term obligations.

IFRX has a Current ratio of 6.50. This is in the better half of the industry: IFRX outperforms 65.70% of its industry peers.

A Quick Ratio of 5.82 indicates that IFRX has no problem at all paying its short term obligations.

With a decent Quick ratio value of 5.82, IFRX is doing good in the industry, outperforming 61.60% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	6.5
Quick Ratio	5.82

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

IFRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -17.91%.

EPS 1Y (TTM)-17.91%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-50%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2QN/A

3.2 Future

Based on estimates for the next years, IFRX will show a very strong growth in Earnings Per Share. The EPS will grow by 36.35% on average per year.

IFRX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 126.25% yearly.

EPS Next Y-18.46%

EPS Next 2Y-5.53%

EPS Next 3Y4.05%

EPS Next 5Y36.35%

Revenue Next Year-1.19%

Revenue Next 2Y25.55%

Revenue Next 3Y102.45%

Revenue Next 5Y126.25%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

IFRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year IFRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.53%

EPS Next 3Y4.05%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for IFRX!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

INFLARX NV

NASDAQ:IFRX (5/3/2024, 7:00:02 PM)

After market: 1.35 -0.03 (-2.17%)

1.38

0 (0%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap81.25M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-35.49%
ROE	-41.59%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	6.5
Quick Ratio	5.82
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-17.91%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y-18.46%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

INFLARX NV (IFRX)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens